Key Takeaways
- Eli Lilly lowered the price of two dosage levels of its weight-loss drug Zepbound for patients paying out of pocket.
- The company also launched new 7.5-mg and 10-mg single-use vials, which cost $499 when refilled every 45 days through Eli Lilly’s new “Zepbound Self Pay Journey Program.”.
- Eli Lilly’s fourth-quarter sales of Zepbound missed analysts’ expectations earlier this month.
Eli Lilly (LLY) on Tuesday lowered the price of its weight-loss drug Zepbound for some patients paying out of pocket and introduced two new available vial doses.
A 2.5-milligram dose of injectable Zepbound will now cost $349 per month and a 5-mg dose of $499 per month, down from a respective $399 and $549 per month, a spokesperson told Investopedia.
The company also launched new 7.5-mg and 10-mg single-use vials, which cost $499 when refilled every 45 days through Eli Lilly’s new “Zepbound Self Pay Journey Program.” The vials “are priced at $599 and $699, respectively, if refilled outside of the 45-day window,” Lilly said.
The offerings are available solely through LillyDirect Self Pay Pharmacy Solutions, which the company said “enables a transparent price by removing third-party supply chain entities and allowing patients to access savings directly outside of insurance.”
Zepbound is approved by the Food and Drug Administration (FDA) for both weight loss and sleep apnea. It is injected once weekly, with recommended maintenance doses of 5 mg, 10 mg, or 15 mg, the company said.
Lilly’s Q4 Zepbound Sales Had Missed Expectations
The price adjustments come after Eli Lilly recently reported fourth-quarter sales of Zepbound and fellow weight-loss drug Mounjaro that missed analysts’ expectations.
Shares of Eli Lilly were up more than 2% intraday Tuesday and have risen 17% over the past 12 months.
:max_bytes(150000):strip_icc()/GettyImages-2126120134-33340f28cc044f788c0fb66c1f66fb73.jpg?w=1200&resize=1200,0&ssl=1&description=Eli+Lilly+Cuts+Price+of+Weight-Loss+Drug+Zepbound+for+Self-Pay+Patients){kind=link}